Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02507154 | Reactivating NK Cells in Treating Refractory Head and Neck Cancer(NKEXPHNC) | unknown | Phase 1 / Phase 2 | 31 | National University Hospital, SingaporeOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT02293850 | Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 18 | Oncolys BioPharma IncINDUSTRY | 2 | Aug 20, 2018 |
| clinicaltrials |
| NCT03631836 | Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma(MARELLE01) | unknown | Phase 1 | 34 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
| NCT03628521 | First-line Combination Treatment Based on Anlotinib | unknown | Phase 1 | 80 | Shanghai Chest HospitalOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT03629847 | Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue | unknown | Phase 1 / Phase 2 | 30 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT02975141 | Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer(AFFECT) | unknown | Phase 1 | 12 | PD Dr. med. Volker HeinemannOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT02919371 | Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) | unknown | Phase 1 / Phase 2 | 77 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT03613428 | Ruxolitinib Plus LVP in Patients With R/R ETP-ALL | unknown | Phase 1 / Phase 2 | 12 | Sichuan UniversityOTHER | 0 | Aug 3, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT03026452 | Effectivity and Safety of Ultrasound-guided Percutaneously Radiofrequency Ablation for Liver Cancer | unknown | Phase 1 / Phase 2 | 400 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT03599778 | XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma | unknown | Phase 1 / Phase 2 | 52 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 26, 2018 | clinicaltrials |
| NCT03601598 | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | unknown | Phase 1 / Phase 2 | 41 | Harbin Medical UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT03528421 | Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients | unknown | Phase 1 | 30 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 16, 2018 | clinicaltrials |
| NCT03283943 | PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. | unknown | Phase 1 | 22 | British Columbia Cancer AgencyOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT03574168 | CD19-CAR-T Cells in Patients With R/R B-ALL | unknown | Phase 1 | 40 | Bioceltech Therapeutics, Ltd.INDUSTRY | 1 | Jun 29, 2018 | clinicaltrials |
| NCT03235973 | Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes(CEREAL) | unknown | Phase 1 | 29 | Institut Paoli-CalmettesOTHER | 1 | Jun 28, 2018 | clinicaltrials |
| NCT03175341 | Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer | unknown | Phase 1 / Phase 2 | 30 | Academic Emergency County Hospital SibiuOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT03560362 | Postoperative Pain Control With Lipossomic Extended Release Bupivacaine | unknown | Phase 1 / Phase 2 | 50 | University of TennesseeOTHER | 1 | Jun 20, 2018 | clinicaltrials |
| NCT03556982 | CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML） | unknown | Phase 1 / Phase 2 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 14, 2018 | clinicaltrials |
| NCT03554889 | Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells | unknown | Phase 1 | 21 | Hangzhou Cancer HospitalOTHER | 1 | Jun 13, 2018 | clinicaltrials |
| NCT02345824 | Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma | unknown | Phase 1 | 3 | University of VirginiaOTHER | 1 | Jun 7, 2018 | clinicaltrials |
| NCT02576301 | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS(AML) | unknown | Phase 1 / Phase 2 | 105 | Mateon TherapeuticsINDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT03544021 | CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL） | unknown | Phase 1 / Phase 2 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02956551 | Personalized DC Vaccine for Lung Cancer(SKLB1608) | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 31, 2018 | clinicaltrials |
| NCT03058809 | Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood | unknown | Phase 1 / Phase 2 | 100 | Viatar LLCINDUSTRY | 0 | May 31, 2018 | clinicaltrials |
| NCT03542799 | EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer(EGFRCART) | unknown | Phase 1 | 20 | Shenzhen Second People's HospitalOTHER | 1 | May 31, 2018 | clinicaltrials |
| NCT03527251 | Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC(SEQUENCE) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT03540303 | Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma | unknown | Phase 1 | 15 | Henan Cancer HospitalOTHER_GOV | 1 | May 30, 2018 | clinicaltrials |
| NCT03516045 | A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer | unknown | Phase 1 / Phase 2 | 65 | Xiangya Hospital of Central South UniversityOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT03525652 | Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment | unknown | Phase 1 / Phase 2 | 30 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT03525782 | Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC | unknown | Phase 1 / Phase 2 | 60 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT03142646 | Safety and Efficacy Evaluation of IM19 CAR-T Cells(IM19CAR-T) | unknown | Phase 1 / Phase 2 | 60 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | May 1, 2018 | clinicaltrials |
| NCT02884479 | An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study | unknown | Phase 1 / Phase 2 | 75 | SciClone Pharmaceuticals International (Cayman) Development LimitedINDUSTRY | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01341834 | Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors | unknown | Phase 1 | 49 | National Cancer Centre, SingaporeOTHER | 1 | Apr 24, 2018 | clinicaltrials |
| NCT03487055 | Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases | unknown | Phase 1 | 30 | Jiangsu T-Mab Biopharma Co.,LtdINDUSTRY | 0 | Apr 3, 2018 | clinicaltrials |
| NCT03242603 | Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells(NKEXPGD2) | unknown | Phase 1 / Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT02955810 | Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)(CyBorD-Dara) | unknown | Phase 1 | 18 | National University of Ireland, Galway, IrelandOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT03474861 | Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Gastrointestinal Cancer | unknown | Phase 1 | 15 | Hangzhou Converd Co., Ltd.INDUSTRY | 0 | Mar 26, 2018 | clinicaltrials |
| NCT01650376 | Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer | unknown | Phase 1 / Phase 2 | 52 | Swedish Medical CenterOTHER | 1 | Mar 23, 2018 | clinicaltrials |
| NCT01451268 | Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)(PANOBEST) | unknown | Phase 1 / Phase 2 | 62 | Johann Wolfgang Goethe University HospitalOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT03468153 | Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma | unknown | Phase 1 / Phase 2 | 10 | Ruijin HospitalOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT02280993 | Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients | unknown | Phase 1 | 72 | Marjolein SpieringOTHER | 4 | Mar 13, 2018 | clinicaltrials |
| NCT03463928 | A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia | unknown | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03456466 | Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 122 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 7, 2018 | clinicaltrials |
| NCT01792102 | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT02840123 | Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines | unknown | Phase 1 | 10 | Fundació Sant Joan de DéuOTHER | 1 | Mar 2, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Aug 21, 2018source: clinicaltrials